Wilma D Heemsbergen

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8207373/wilma-d-heemsbergen-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34 papers	953 citations	12 h-index	30 g-index
55 ext. papers	1,227 ext. citations	2.8 avg, IF	4.02 L-index

#	Paper	IF	Citations
34	Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.. *Oral Oncology*, **2022**, 127, 105782	4.4	1
33	Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. *Physics in Medicine and Biology*, **2021**, 66,	3.8	4
32	Association between incidental dose outside the prostate and tumor control after modern image-guided radiotherapy. *Physics and Imaging in Radiation Oncology*, **2021**, 17, 25-31	3.1	3
31	Radiotherapy Practice for Treatment of Bone Metastasis in Ethiopia. *JCO Global Oncology*, **2020**, 6, 1422-1427	3.7	1
30	Automated Radiotherapy Planning for Patient-Specific Exploration of the Trade-Off Between Tumor Dose Coverage and Predicted Radiation-Induced Toxicity-A Proof of Principle Study for Prostate Cancer. *Frontiers in Oncology*, **2020**, 10, 943	5.3	2
29	Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial. *Frontiers in Oncology*, **2020**, 10, 469	5.3	7
28	The Risk of Second Primary Cancers in Prostate Cancer Survivors Treated in the Modern Radiotherapy Era. *Frontiers in Oncology*, **2020**, 10, 605119	5.3	2
27	Patient-reported acute GI symptoms in locally advanced cervical cancer patients correlate with rectal dose. *Radiotherapy and Oncology*, **2020**, 148, 38-43	5.3	3
26	Long-term outcomes following stereotactic body radiotherapy boost for oropharyngeal squamous cell carcinoma. *Acta Oncologica*, **2019**, 58, 926-933	3.2	3
25	The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT). *Radiotherapy and Oncology*, **2019**, 130, 25-31	5.3	42
24	Internal Mammary Chain Sentinel Nodes in Early-Stage Breast Cancer Patients: Toward Selective Removal. *Annals of Surgical Oncology*, **2019**, 26, 945-953	3.1	3
23	Prediction of early mortality following stereotactic body radiotherapy for peripheral early-stage lung cancer. *Acta Oncologica*, **2019**, 58, 237-242	3.2	6
22	Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer. *Head and Neck*, **2019**, 41, 1387-1394	4.2	10
21	Locoregional failures and their relation to radiation fields following stereotactic body radiotherapy boost for oropharyngeal squamous cell carcinoma. *Head and Neck*, **2019**, 41, 1622-1631	4.2	3
20	Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology. *European Journal of Radiology*, **2018**, 98, 107-112	4.7	20
19	In Reply to Gi gi et al. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 1291-1292	4	
18	Breast-shape changes during radiation therapy after breast-conserving surgery. *Physics and Imaging in Radiation Oncology*, **2018**, 6, 71-76	3.1	5

17	Hyoid bone displacement as parameter for swallowing impairment in patients treated for advanced head and neck cancer. *European Archives of Oto-Rhino-Laryngology*, **2017**, 274, 597-606	3.5	15
16	A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor response. *Clinical and Translational Radiation Oncology*, **2017**, 6, 1-6	4.6	4
15	Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy. *Radiotherapy and Oncology*, **2017**, 122, 224-228	5.3	12
14	Orthovoltage for basal cell carcinoma of the head and neck: Excellent local control and low toxicity profile. *Laryngoscope*, **2016**, 126, 1796-802	3.6	9
13	Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 1061-1069	21.7	255
12	Radiation dose to the tongue and velopharynx predicts acoustic-articulatory changes after chemo-IMRT treatment for advanced head and neck cancer. *European Archives of Oto-Rhino-Laryngology*, **2016**, 273, 487-94	3.5	11
11	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 464-474	21.7	150
10	Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO Trial. *Journal of Sexual Medicine*, **2016**, 13, 1695-1703	1.1	5
9	Dose-surface maps identifying local dose-effects for acute gastrointestinal toxicity after radiotherapy for prostate cancer. *Radiotherapy and Oncology*, **2015**, 117, 515-20	5.3	47
8	Impact of tumour invasion on seminal vesicles mobility in radiotherapy of prostate cancer. *Radiotherapy and Oncology*, **2015**, 117, 283-7	5.3	7
7	Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. *World Journal of Surgery*, **2015**, 39, 453-60	3.3	36
6	Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. *Radiotherapy and Oncology*, **2014**, 110, 104-9	5.3	136
5	Dysphagia and trismus after concomitant chemo-Intensity-Modulated Radiation Therapy (chemo-IMRT) in advanced head and neck cancer; dose-effect relationships for swallowing and mastication structures. *Radiotherapy and Oncology*, **2013**, 106, 364-9	5.3	86
4	Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: results from a randomized trial. *Radiotherapy and Oncology*, **2013**, 107, 134-9	5.3	18
3	Sequentially delivered boost plans are superior to simultaneously delivered plans in head and neck cancer when the boost volume is located further away from the parotid glands. *Radiotherapy and Oncology*, **2011**, 98, 51-6	5.3	8
2	Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. *Radiotherapy and Oncology*, **2010**, 96, 13-8	5.3	27
1	Controversies in the treatment of high-risk prostate cancer--what is the optimal combination of hormonal therapy and radiotherapy: a review of literature. *Prostate*, **2010**, 70, 701-9	4.2	9